NCT00784277: A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease |
|
|
| Completed | 3 | 597 | US | oxycodone CR, oxycodone IR, Tapentadol ER (CG5503), Tapentadol IR (CG5503), placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH | Joint Diseases, Arthritis, Osteoarthritis | 07/09 | 07/09 | | |
NCT01427283 / 2011-005061-20: A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain |
|
|
| Completed | 3 | 450 | US | Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, OxyContin, Placebo | Purdue Pharma LP | Low Back Pain | 10/14 | 10/14 | | |
NCT01427270 / 2011-005060-26: Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain |
|
|
| Completed | 3 | 455 | Europe, US | Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, OxyContin, Placebo | Purdue Pharma LP | Low Back Pain | 10/14 | 10/14 | | |
